Samsung Invests In Biologics | Chemical & Engineering News
Volume 93 Issue 48 | p. 27 | Concentrates
Issue Date: December 7, 2015

Samsung Invests In Biologics

Department: Business
Keywords: biopharmaceutical, mammalian cells, contract manufacturing, South korea

Samsung BioLogics will spend $730 million to build a biologics facility at its site in Songdo, South Korea. The new plant, the company’s third, will feature 180,000 L of fermentation capacity for mammalian-cell-culture-based biologics. Samsung BioLogics employs 1,000 people and expects its headcount will rise to 1,800 in 2018 when the plant comes on-line. The contract manufacturer is majority-owned by Samsung Electronics and other Samsung firms.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment